Edit Entry

Xiaofeng Wang, PhD

Title(s):
Assistant Professor of Molecular and Systems Biology

Department(s):
Molecular and Systems Biology

Education:
Tsinghua University, Cancer Biology, Ph.D. '11
Sichuan University, Biological Sciences, B.S. '05

Programs:
Molecular and Cellular Biology Graduate Programs
Program in Experimental and Molecular Medicine

Websites:
https://www.dartmouth.edu/~mcb/research/faculty.html
https://graduate.dartmouth.edu/pemm/people/xiaofeng-wang

Contact Information:

1 Medical Center Dr
Rubin 632
Lebanon NH 03756

Phone: 603-653-9974
Email: Xiaofeng.Wang@Dartmouth.edu


Professional Interests:

Our work focuses on cancer epigenetics. We are particularly interested in studying a family of chromatin remodeling SWI/SNF(BAF) complexes, which are frequently mutated in a variety of human cancers. Our work is aimed to understand how these mutations cause cancer, focusing on the regulation of chromatin structure dynamics (SWI/SNF epigenome) and chromatin remodeler protein complex assembly (SWI/SNF interactome), as well as using genetic and chemical screens to identify potential therapeutic targets in human cancers.

We have found that SWI/SNF complex is essential for enhancer activation and super-enhancer maintenance, and certain subunits are crucial to maintain the stability and abundance of the complex in cancers (Nature Genetics, 2017; Nature Communications, 2017). It remains unclear how the complex regulates the enhancer landscapes in normal and cancer cells and how different subunits contribute to the complex assembly and targeting on chromatin. Meanwhile, using high-throughput genome-wide loss-of-function screens (shRNA and CRISPR-Cas9), we have found that SWI/SNF mutations create specific paralog dependencies in cancer (Nature Medicine 2014; Cancer Cell, 2014), pointing to potential therapeutic benefits.

Current research in the lab is focused on studying the genome-wide targeting of SWI/SNF complex in cancer and its role in regulating chromatin structures; identifying novel interacting proteins and co-regulators; searching for cancer specific vulnerabilities using genome-wide CRISPR-Cas9 screens.

Grant Information:

R00CA197640 (PI:Wang) 04/01/16 – 03/31/21
NIH NCI K99/R00 Pathway to Independence Award
Project: “Role of SNF5 in regulating SWI/SNF complex assembly & targeting in rhabdoid tumor"
Role: PI


Selected Publications:

 

  • Wang X*, Lee RS*, Alver BH*, Haswell JR, Wang S, Mieczkowski J, Drier Y, Gillespie SM, Archer TC, Wu JN, Tzvetkov EP, Troisi EC, Pomeroy SL, Biegel JA, Tolstorukov MY, Bernstein BE, Park PJ, and Roberts CW. (*Co-first author) SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation. Nat Genet. 2017;49(2):289-295 (view details on MedLine)

  • Mathur R, Alver BH, San Roman AK, Wilson BG, Wang X, Agoston AT, Park PJ, Shivdasani RA, Roberts CW. ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice. Nature Genetics. 2017; 49(2):296-302. (view details on MedLine)

  • Kim KH*, Alver BH*, Lu P*, Wang X, Manchester HE, Wang W, Haswell JR, Park PJ, and Roberts CW. (*Co-first author) The SWI/SNF chromatin remodelling complex is required for maintenance of lineage specific enhancers. Nat Commun. 2017 Mar 6;8:14648 (view details on MedLine)

  • Vierbuchen T, Ling E, Cowley CJ, Couch CH, Wang X, Harmin DA, Roberts CWM, Greenberg ME. AP-1 Transcription Factors and the BAF Complex Mediate Signal-Dependent Enhancer Selection. Molecular Cell. 2017, 68(6):1067-1082. (view details on MedLine)

  • Helming KC*, Wang X*, Roberts CW. (*Co-first author) Vulnerabilities of Mutant SWI/SNF Complexes in Cancer. Cancer Cell. 2014, 26 (3):309-317 (view details on MedLine)

  • Helming KC, Wang X*, Wilson BG, Vazquez F, Haswell JR, Manchester HE, Kim Y, Kryukov GV, Ghandi M, Aguirre AJ, Jagani Z, Wang Z, Garraway LA, Hahn WC, Roberts CW. (*Co-first author) ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med. 2014, 20 (3):251-4. (view details on MedLine)

  • Wang X, Haswell JR, Roberts CW. Molecular Pathways: SWI/SNF (BAF) Complexes Are Frequently Mutated in Cancer--Mechanisms and Potential Therapeutic Insights. Clin Cancer Res. 2013, 20(1):21-7 (view details on MedLine)